Idaho will receive $1.33 million from a settlement between drug company GlaxoSmithKline LLC and 37 other state attorneys general, Attorney General Lawrence Wasden said Thursday.

GlaxoSmithKline admitted no wrongdoing but agreed to pay $90 million to resolve allegations that it unlawfully promoted diabetes drug Avandia.

The states allege that GlaxoSmithKline falsely claimed Avandia had cardiovascular benefits. The drug may actually increase cardiovascular risks, Wasden said.

GlaxoSmithKline also agreed not to make false, misleading or deceptive claims about any diabetes drug or a drug's safety; not to offer favorable information when that information has been found incorrect; not to promote investigational drugs; and not to misuse statistics or otherwise misrepresent clinical trials.

The money paid to Idaho from the settlement will be deposited in the consumer protection account, subject to appropriation by the Idaho Legislature. This is the third settlement Wasden's consumer protection division has reached with GlaxoSmithKline.